Actively Recruiting
Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates
Led by Universitaire Ziekenhuizen KU Leuven · Updated on 2024-07-03
60
Participants Needed
1
Research Sites
480 weeks
Total Duration
On this page
Sponsors
U
Universitaire Ziekenhuizen KU Leuven
Lead Sponsor
K
KU Leuven
Collaborating Sponsor
AI-Summary
What this Trial Is About
This prospective study will compare the pharmacokinetic exposure to liposomal amphotericin B between critically ill patients and non-critically ill (hematology) patients in an early and late exposure day.
CONDITIONS
Official Title
Pharmacokinetics of Liposomal Amphotericin B in Critically Ill vs. Non-critically Ill Hematological Patients: Exploration of Covariates
Who Can Participate
Eligibility Criteria
You may qualify if you...
- Treatment with L-AmB
- Admitted to an ICU or Hematology ward
You will not qualify if you...
- DNR 2 or 3
- Pregnant or lactating women
- Previous documentation of intolerance/sensitivity to L-AmB
AI-Screening
AI-Powered Screening
Complete this quick 3-step screening to check your eligibility
Trial Site Locations
Total: 1 location
1
UZ Leuven
Leuven, Belgium, 3000
Actively Recruiting
Research Team
R
Ruth Van Daele, PharmD
CONTACT
I
Isabel Spriet, PharmD, PhD
CONTACT
How is the study designed?
Study Type
OBSERVATIONAL
Masking
N/A
Allocation
N/A
Model
N/A
Primary Purpose
N/A
Number of Arms
2
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here